Fecal Calprotectin Test Market Is Estimated To Witness High Growth Owing To Increasing Adoption Of Point-Of-Care Testing
The Fecal Calprotectin Test market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 12.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Fecal calprotectin is a protein that is present in the cytoplasm of neutrophils. When inflamed neutrophils release Calprotectin into the intestines during gastrointestinal inflammation, it ends up in the feces. Therefore, measuring fecal Calprotectin levels can help determine the presence and severity of gastrointestinal inflammation. Fecal Calprotectin tests are used to aid in the diagnosis of gastrointestinal conditions such as inflammatory bowel disease. These tests can help distinguish between irritable bowel syndrome and inflammatory bowel disease.
Market Dynamics:
The increasing adoption of point-of-care testing is expected to drive the growth of the Fecal Calprotectin Test Market. Point-of-care testing allows instant diagnosis and treatment by delivering results within minutes compared to conventional laboratory testing which can take days. POC testing provides convenience to patients as they do not need to visit laboratories for sample collection and can get results when meeting healthcare professionals. This helps in faster clinical decision making.
The increasing incidence of gastrointestinal disorders such as Inflammatory Bowel Disease is also expected to support market growth. According to the Crohn’s & Colitis Foundation, inflammatory bowel disease affects approximately 3 million Americans. Conditions such as Crohn's disease and ulcerative colitis can cause gastrointestinal inflammation which needs to be diagnosed and monitored. Fecal Calprotectin tests aid in the diagnosis and management of such inflammatory conditions by detecting gastrointestinal inflammation.
SWOT Analysis
Strength: The fecal calprotectin test has high sensitivity and specificity for detecting intestinal inflammation. It is a non-invasive test and does not require any special diets or medication withdrawals. Samples can easily be collected and shipped to laboratories for analysis.
Weakness: The test results may not accurately differentiate between infectious and inflammatory causes of gastrointestinal symptoms. Sample stability can be an issue if not stored and transported properly.
Opportunity: Rising incidence of inflammatory bowel diseases provides major growth opportunities. Increasing adoption of this test by gastroenterologists for evaluating patients with abdominal pain can drive the market.
Threats: Alternative tests like fecal occult blood tests and endoscopy pose competition. Strict regulations for commercialization of diagnostic kits may hamper flexibility of market players.
Key Takeaways
The Global Fecal Calprotectin Test Market Size is expected to witness high growth, exhibiting a CAGR of 12.3% over the forecast period, due to increasing prevalence of inflammatory bowel diseases. The market size for 2023 is US$ 140.6 Mn.
Regional analysis
North America dominates the global market owing to advanced healthcare facilities and rising gastrointestinal disorders. Europe accounts for the second largest share due to supportive government initiatives and increasing public awareness. Asia Pacific exhibits the fastest growth due to improving access to healthcare and rising medical tourism.
Key players
Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO.